ArticleInternational journal of molecular sciences2025
Retrotransposon Protein L1 ORF1p Expression in Aging Central Nervous System.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The long-interspersed elements (LINE-1; L1) represent the main active family of retrotransposons in the human organism, comprising approximately 17% of its content. L1 sequence codifies for the two proteins involved in its retrotransposition: ORF1p, an RNA binding protein, and ORF2p, endowed with endonuclease and reverse transcriptase activity. The vast majority of L1 copies are inactive, with only a small percentage retaining their retrotransposition capacity, posing a threat to the organism due to its mutagenic potential. To mitigate such risks, mammals have evolved intricate regulatory mechanisms, including heterochromatin formation and RNA degradation pathways. Age-related diminution in these regulatory pathways may be particularly important within the Central Nervous System (CNS), where cellular regeneration is limited, and genomic integrity is critical for lifelong function. Here, we describe an age-associated upregulation of ORF1p in the mouse brain, indicating a potential role of L1 activity in aging. We further demonstrate the presence of ORF1p across diverse CNS cell types, including neurons, oligodendrocytes and microglia. Notably, we observe a correlation between ORF1p presence and microglial activation, a hallmark of neuroinflammation, during aging. This study advances our understanding of L1 dynamics in the CNS and underscores the significance of L1 in age-related neurological changes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.